Press Release RSS Feed (opens in new window)

Press Releases

Press release year list 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
December 15, 2015
Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma
December 15, 2015
Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data
December 14, 2015
New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports
December 3, 2015
Retrospective Analysis Shows Optune Safe in Glioblastoma Patients with Implanted Non-Programmable Shunts
December 2, 2015
Preliminary Phase 2 Data Demonstrate Tumor Treating Fields is Safe in Patients with Brain Metastases Originating from Non-Small Cell Lung Cancer
November 20, 2015
New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence
November 17, 2015
Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015
November 17, 2015
Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data
October 26, 2015
Novocure Reports Third Quarter 2015 Operating and Financial Results
October 19, 2015
NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option
October 16, 2015
Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015
October 16, 2015
Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26
October 9, 2015
ADDING MULTIMEDIA FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
October 7, 2015
NovoCure Limited Announces Closing of Initial Public Offering
October 5, 2015
Novocure Announces CE Mark and First Patient Use of Second Generation Optune System
October 2, 2015
NovoCure Limited Announces Launch of Initial Public Offering
September 21, 2015
NovoCure Limited Announces Launch of Initial Public Offering
September 9, 2015
Novocure to Present the Latest Data from the EF-14 Clinical Trial in Newly Diagnosed GBM at the 15th Interim Meeting of the World Federation of Neurosurgical Societies
September 8, 2015
Novocure Announces Optune Now Available at more than 200 Leading Cancer Centers across the United States
September 4, 2015
Novocure to Present Clinical Trial Designs and Preclinical Data on Tumor Treating Fields at the 16th World Conference on Lung Cancer
August 26, 2015
Data on Tumor Treating Fields to be Presented at the 37th Annual Conference of the IEEE Engineering in Medicine and Biology Society
August 5, 2015
Novocure Selected as Technology Pioneer by World Economic Forum
July 9, 2015
Novocure Launches Clinical Trial Website at www.novocuretrials.com
May 28, 2015
Novocure Hosts First Glioblastoma-focused Hackathon to Develop New Support Tools for the GBM Brain Cancer Community
May 28, 2015
Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial
May 27, 2015
Novocure Announces Commercial Launch of Optune (the NovoTTF-100A System) in Japan
May 13, 2015
Novocure to Present New Clinical and Preclinical Data on Tumor Treating Fields at the American Society of Clinical Oncology Annual Meeting 2015
May 11, 2015
NCCN Guidelines Recommend Tumor Treating Fields as a Standard Treatment Option for Recurrent Glioblastoma
May 11, 2015
FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma
May 5, 2015
Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Address Challenges in the Glioblastoma Community
April 10, 2015
New Preclinical Data on Tumor Treating Fields to be presented at the American Association for Cancer Research Annual Meeting 2015
April 9, 2015
Intersect ENT Appoints Kieran Gallahue and Tony Vernon to Board of Directors
March 30, 2015
Novocure Announces Japanese Approval of Optune (the NovoTTF-100A System) for Treatment of Recurrent Glioblastoma
February 23, 2015
Novocure Enrolls the First Patient in its Phase II STELLAR Trial of Tumor Treating Fields Together with Pemetrexed and Cisplatin or Carboplatin for the Treatment of Malignant Mesothelioma
January 12, 2015
Novocure Announces the Completion of Enrollment of its PANOVA Trial of Tumor Treating Fields Plus Gemcitabine for Treatment of Pancreatic Cancer
January 8, 2015
Novocure Announces $100 Million Term Loan Agreement with Pharmakon Advisors